{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T21:52:21Z","timestamp":1793829141457,"version":"4.6.1"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"FightMND in the form of Drug Development Grants (DDG-137). Motor Neuron Disease Research Australia","id":[{"id":"https:\/\/ror.org\/04es2gg88","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The accumulation of misfolded proteins underlies a broad range of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS). Due to their dynamic nature, these misfolded proteins have proven challenging to target therapeutically. Here, we specifically target misfolded disease variants of the ALS-associated protein superoxide dismutase 1 (SOD1), using a biological proteolysis targeting chimera (BioPROTAC) composed of a SOD1-specific intrabody and an E3 ubiquitin ligase. Screening of intrabodies and E3 ligases for optimal BioPROTAC construction reveals a candidate capable of degrading multiple disease variants of SOD1, preventing their aggregation in cells. Using CRISPR\/Cas9 technology to develop a BioPROTAC transgenic mouse line, we demonstrate that the presence of the BioPROTAC delays disease progression in the SOD1\n                    <jats:sup>G93A<\/jats:sup>\n                    mouse model of ALS. Delayed disease progression is associated with protection of motor neurons, a reduction of insoluble SOD1 accumulation and preservation of innervated neuromuscular junctions. These findings provide proof-of-concept evidence and a platform for developing BioPROTACs as a therapeutic strategy for the targeted degradation of neurotoxic misfolded species in the context of neurodegenerative diseases.\n                  <\/jats:p>","DOI":"10.1038\/s41467-025-65481-w","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T10:02:18Z","timestamp":1762768938000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Development of a targeted BioPROTAC degrader selective for misfolded SOD1"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3057-7113","authenticated-orcid":false,"given":"Christen G.","family":"Chisholm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9199-1326","authenticated-orcid":false,"given":"Rachael","family":"Bartlett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3464-3480","authenticated-orcid":false,"given":"Mikayla L.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma-Jayne","family":"Proctor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie E.","family":"Farrawell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jody","family":"Gorman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7944-2108","authenticated-orcid":false,"given":"Fabien","family":"Delerue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars M.","family":"Ittner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6871-1149","authenticated-orcid":false,"given":"Kara L.","family":"Vine-Perrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7574-0044","authenticated-orcid":false,"given":"Heath","family":"Ecroyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0080-1006","authenticated-orcid":false,"given":"Neil R.","family":"Cashman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0924-0513","authenticated-orcid":false,"given":"Darren N.","family":"Saunders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"McAlary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2133-9308","authenticated-orcid":false,"given":"Jeremy S.","family":"Lum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin J.","family":"Yerbury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,10]]},"reference":[{"key":"65481_CR1","doi-asserted-by":"publisher","first-page":"e202300712","DOI":"10.1002\/cbic.202300712","volume":"25","author":"DA Nalawansha","year":"2024","unstructured":"Nalawansha, D. A., Mangano, K., den Besten, W. & Potts, P. R. TAC-tics for leveraging proximity biology in drug discovery. ChemBioChem 25, e202300712 (2024).","journal-title":"ChemBioChem"},{"key":"65481_CR2","doi-asserted-by":"publisher","first-page":"8554","DOI":"10.1073\/pnas.141230798","volume":"98","author":"KM Sakamoto","year":"2001","unstructured":"Sakamoto, K. M. et al. Protacs: chimeric molecules that target proteins to the Skp1\u2013Cullin\u2013F box complex for ubiquitination and degradation. Proc. Natl. Acad. Sci. USA 98, 8554\u20138559 (2001).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"65481_CR3","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1136\/jmedgenet-2020-106866","volume":"58","author":"EP McCann","year":"2021","unstructured":"McCann, E. P. et al. Evidence for polygenic and oligogenic basis of Australian sporadic amyotrophic lateral sclerosis. J. Med. Genet. 58, 87 (2021).","journal-title":"J. Med. Genet."},{"key":"65481_CR4","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/ng0596-43","volume":"13","author":"AG Reaume","year":"1996","unstructured":"Reaume, A. G. et al. Motor neurons in Cu\/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury. Nat. Genet. 13, 43\u201347 (1996).","journal-title":"Nat. Genet."},{"key":"65481_CR5","doi-asserted-by":"publisher","first-page":"e1000350","DOI":"10.1371\/journal.pgen.1000350","volume":"5","author":"J Wang","year":"2009","unstructured":"Wang, J. et al. An ALS-linked mutant SOD1 produces a locomotor defect associated with aggregation and synaptic dysfunction when expressed in neurons of Caenorhabditis elegans. PLoS Genet. 5, e1000350 (2009).","journal-title":"PLoS Genet."},{"key":"65481_CR6","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/j.1471-4159.2007.04531.x","volume":"102","author":"SA Ezzi","year":"2007","unstructured":"Ezzi, S. A., Urushitani, M. & Julien, J. P. Wild-type superoxide dismutase acquires binding and toxic properties of ALS-linked mutant forms through oxidation. J. Neurochem. 102, 170\u2013178 (2007).","journal-title":"J. Neurochem."},{"key":"65481_CR7","doi-asserted-by":"publisher","first-page":"5074","DOI":"10.1073\/pnas.1115402109","volume":"109","author":"S Guareschi","year":"2012","unstructured":"Guareschi, S. et al. An over-oxidized form of superoxide dismutase found in sporadic amyotrophic lateral sclerosis with bulbar onset shares a toxic mechanism with mutant SOD1. Proc. Natl. Acad. Sci. USA 109, 5074\u20135079 (2012).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"65481_CR8","doi-asserted-by":"publisher","first-page":"3620","DOI":"10.1073\/pnas.1312245111","volume":"111","author":"LI Grad","year":"2014","unstructured":"Grad, L. I. et al. Intercellular propagated misfolding of wild-type Cu\/Zn superoxide dismutase occurs via exosome-dependent and -independent mechanisms. Proc. Natl. Acad. Sci. USA 111, 3620\u20133625 (2014).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"65481_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-31773-z","volume":"8","author":"B Par\u00e9","year":"2018","unstructured":"Par\u00e9, B. et al. Misfolded SOD1 pathology in sporadic Amyotrophic Lateral Sclerosis. Sci. Rep. 8, 14223 (2018).","journal-title":"Sci. Rep."},{"key":"65481_CR10","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s00401-011-0805-3","volume":"121","author":"K Forsberg","year":"2011","unstructured":"Forsberg, K., Andersen, P. M., Marklund, S. L. & Br\u00e4nnstr\u00f6m, T. Glial nuclear aggregates of superoxide dismutase-1 are regularly present in patients with amyotrophic lateral sclerosis. Acta Neuropathol. 121, 623\u2013634 (2011).","journal-title":"Acta Neuropathol."},{"key":"65481_CR11","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00401-017-1688-8","volume":"134","author":"S Da Cruz","year":"2017","unstructured":"Da Cruz, S. et al. Misfolded SOD1 is not a primary component of sporadic ALS. Acta Neuropathol. 134, 97\u2013111 (2017).","journal-title":"Acta Neuropathol."},{"key":"65481_CR12","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s00401-010-0646-5","volume":"119","author":"A Kerman","year":"2010","unstructured":"Kerman, A. et al. Amyotrophic lateral sclerosis is a non-amyloid disease in which extensive misfolding of SOD1 is unique to the familial form. Acta Neuropathol. 119, 335\u2013344 (2010).","journal-title":"Acta Neuropathol."},{"key":"65481_CR13","doi-asserted-by":"publisher","first-page":"336","DOI":"10.3389\/fncel.2015.00336","volume":"9","author":"F Tafuri","year":"2015","unstructured":"Tafuri, F., Ronchi, D., Magri, F., Comi, G. P. & Corti, S. SOD1 misplacing and mitochondrial dysfunction in amyotrophic lateral sclerosis pathogenesis. Front. Cell. Neurosci. 9, 336 (2015).","journal-title":"Front. Cell. Neurosci."},{"key":"65481_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-016-0313-8","volume":"4","author":"S Pickles","year":"2016","unstructured":"Pickles, S. et al. ALS-linked misfolded SOD1 species have divergent impacts on mitochondria. Acta Neuropathol. Commun. 4, 43 (2016).","journal-title":"Acta Neuropathol. Commun."},{"key":"65481_CR15","doi-asserted-by":"publisher","first-page":"4668","DOI":"10.1093\/hmg\/ddx348","volume":"26","author":"A Moller","year":"2017","unstructured":"Moller, A., Bauer, C. S., Cohen, R. N., Webster, C. P. & De Vos, K. J. Amyotrophic lateral sclerosis-associated mutant SOD1 inhibits anterograde axonal transport of mitochondria by reducing Miro1 levels. Hum. Mol. Genet. 26, 4668\u20134679 (2017).","journal-title":"Hum. Mol. Genet."},{"key":"65481_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mad.2016.01.005","volume":"154","author":"Y Zhang","year":"2016","unstructured":"Zhang, Y. et al. Liver specific expression of Cu\/ZnSOD extends the lifespan of Sod1 null mice. Mech. Ageing Dev. 154, 1\u20138 (2016).","journal-title":"Mech. Ageing Dev."},{"key":"65481_CR17","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1056\/NEJMc1905039","volume":"381","author":"PM Andersen","year":"2019","unstructured":"Andersen, P. M. et al. Phenotype in an Infant with SOD1 Homozygous Truncating Mutation. N. Engl. J. Med. 381, 486\u2013488 (2019).","journal-title":"N. Engl. J. Med."},{"key":"65481_CR18","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1093\/brain\/awz182","volume":"142","author":"JH Park","year":"2019","unstructured":"Park, J. H. et al. SOD1 deficiency: a novel syndrome distinct from amyotrophic lateral sclerosis. Brain 142, 2230\u20132237 (2019).","journal-title":"Brain"},{"key":"65481_CR19","doi-asserted-by":"publisher","first-page":"e645","DOI":"10.1212\/NXG.0000000000000645","volume":"8","author":"D Gagliardi","year":"2022","unstructured":"Gagliardi, D. et al. Homozygous SOD1 variation L144S produces a severe form of Amyotrophic Lateral Sclerosis in an Iranian family. Neurol. Genet. 8, e645 (2022).","journal-title":"Neurol. Genet."},{"key":"65481_CR20","first-page":"E1121","volume":"111","author":"C Yang","year":"2014","unstructured":"Yang, C. et al. Partial loss of TDP-43 function causes phenotypes of amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. USA 111, E1121\u2013E1129 (2014).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"65481_CR21","doi-asserted-by":"crossref","unstructured":"Kingwell, K. Double setback for ASO trials in Huntington disease. https:\/\/www-nature-com.ezproxy.uow.edu.au\/articles\/d41573-021-00088-6 (2021).","DOI":"10.1038\/d41573-021-00088-6"},{"key":"65481_CR22","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nrd.2016.211","volume":"16","author":"AC Lai","year":"2017","unstructured":"Lai, A. C. & Crews, C. M. Induced protein degradation: an emerging drug discovery paradigm. Nat. Rev. Drug Discov. 16, 101\u2013114 (2017).","journal-title":"Nat. Rev. Drug Discov."},{"key":"65481_CR23","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.cbpa.2019.02.022","volume":"50","author":"S-L Paiva","year":"2019","unstructured":"Paiva, S.-L. & Crews, C. M. Targeted protein degradation: elements of PROTAC design. Curr. Opin. Chem. Biol. 50, 111\u2013119 (2019).","journal-title":"Curr. Opin. Chem. Biol."},{"key":"65481_CR24","doi-asserted-by":"publisher","first-page":"3500","DOI":"10.1200\/JCO.2020.38.15_suppl.3500","volume":"38","author":"DP Petrylak","year":"2020","unstructured":"Petrylak, D. P. et al. First-in-human phase I study of ARV-110, an androgen receptor (AR) PROTAC degrader in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) following enzalutamide (ENZ) and\/or abiraterone (ABI). J. Clin. Oncol. 38, 3500\u20133500 (2020).","journal-title":"J. Clin. Oncol."},{"key":"65481_CR25","doi-asserted-by":"crossref","unstructured":"Hamilton, E. P. et al. ARV-471, an estrogen receptor (ER) PROTAC degrader, combined with palbociclib in advanced ER+\/human epidermal growth factor receptor 2\u2013negative (HER2-) breast cancer: Phase 1b cohort (part C) of a phase 1\/2 study. J. Clin. Oncol. 40, TPS1120\u2013TPS1120 (2022).","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS1120"},{"key":"65481_CR26","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.tips.2023.03.003","volume":"44","author":"Y Fang","year":"2023","unstructured":"Fang, Y. et al. Targeted protein degrader development for cancer: advances, challenges, and opportunities. Trends Pharmacol. Sci. 44, 303\u2013317 (2023).","journal-title":"Trends Pharmacol. Sci."},{"key":"65481_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42546-2","volume":"14","author":"A Fletcher","year":"2023","unstructured":"Fletcher, A. et al. A TRIM21-based bioPROTAC highlights the therapeutic benefit of HuR degradation. Nat. Commun. 14, 7093 (2023).","journal-title":"Nat. Commun."},{"key":"65481_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50235-x","volume":"15","author":"A Chan","year":"2024","unstructured":"Chan, A. et al. Lipid-mediated intracellular delivery of recombinant bioPROTACs for the rapid degradation of undruggable proteins. Nat. Commun. 15, 5808 (2024).","journal-title":"Nat. Commun."},{"key":"65481_CR29","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/j.neuron.2024.01.022","volume":"112","author":"YD Ke","year":"2024","unstructured":"Ke, Y. D. et al. Targeting 14-3-3\u03b8-mediated TDP-43 pathology in amyotrophic lateral sclerosis and frontotemporal dementia mice. Neuron 112, 1249\u20131264.e8 (2024).","journal-title":"Neuron"},{"key":"65481_CR30","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.1021\/acschembio.8b00729","volume":"13","author":"RS Atlasi","year":"2018","unstructured":"Atlasi, R. S. et al. Investigation of anti-SOD1 antibodies yields new structural insight into SOD1 misfolding and surprising behavior of the antibodies themselves. ACS Chem. Biol. 13, 2794\u20132807 (2018).","journal-title":"ACS Chem. Biol."},{"key":"65481_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/srep22155","volume":"6","author":"E Pokrishevsky","year":"2016","unstructured":"Pokrishevsky, E., Grad, L. I. & Cashman, N. R. TDP-43 or FUS-induced misfolded human wild-type SOD1 can propagate intercellularly in a prion-like fashion. Sci. Rep. 6, 22155 (2016).","journal-title":"Sci. Rep."},{"key":"65481_CR32","doi-asserted-by":"publisher","first-page":"107207","DOI":"10.1016\/j.jbc.2024.107207","volume":"300","author":"E Pokrishevsky","year":"2024","unstructured":"Pokrishevsky, E. et al. Tryptophan residues in TDP-43 and SOD1 modulate the cross-seeding and toxicity of SOD1. J. Biol. Chem. 300, 107207 (2024).","journal-title":"J. Biol. Chem."},{"key":"65481_CR33","doi-asserted-by":"publisher","first-page":"135553","DOI":"10.1016\/j.neulet.2020.135553","volume":"742","author":"Y Xia","year":"2021","unstructured":"Xia, Y. et al. Novel SOD1 monoclonal antibodies against the electrostatic loop preferentially detect misfolded SOD1 aggregates. Neurosci. Lett. 742, 135553 (2021).","journal-title":"Neurosci. Lett."},{"key":"65481_CR34","doi-asserted-by":"publisher","first-page":"4022","DOI":"10.1073\/pnas.0712209105","volume":"105","author":"C Vande Velde","year":"2008","unstructured":"Vande Velde, C., Miller, T. M., Cashman, N. R. & Cleveland, D. W. Selective association of misfolded ALS-linked mutant SOD1 with the cytoplasmic face of mitochondria. Proc. Natl. Acad. Sci. USA 105, 4022\u20134027 (2008).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"65481_CR35","doi-asserted-by":"publisher","first-page":"jcs209122","DOI":"10.1242\/jcs.209122","volume":"131","author":"NE Farrawell","year":"2018","unstructured":"Farrawell, N. E. et al. SOD1(A4V) aggregation alters ubiquitin homeostasis in a cell model of ALS. J. Cell Sci. 131, jcs209122 (2018).","journal-title":"J. Cell Sci."},{"key":"65481_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/srep13416","volume":"5","author":"NE Farrawell","year":"2015","unstructured":"Farrawell, N. E. et al. Distinct partitioning of ALS associated TDP-43, FUS and SOD1 mutants into cellular inclusions. Sci. Rep. 5, 13416 (2015).","journal-title":"Sci. Rep."},{"key":"65481_CR37","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.nbd.2012.08.010","volume":"49","author":"TE Brotherton","year":"2013","unstructured":"Brotherton, T. E., Li, Y. & Glass, J. D. Cellular toxicity of mutant SOD1 protein is linked to an easily soluble, non-aggregated form in vitro. Neurobiol. Dis. 49, 49\u201356 (2013).","journal-title":"Neurobiol. Dis."},{"key":"65481_CR38","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1021\/acschembio.7b00485","volume":"12","author":"P Ottis","year":"2017","unstructured":"Ottis, P. et al. Assessing Different E3 Ligases for Small Molecule Induced Protein Ubiquitination and Degradation. ACS Chem. Biol. 12, 2570\u20132578 (2017).","journal-title":"ACS Chem. Biol."},{"key":"65481_CR39","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.molcel.2020.04.032","volume":"79","author":"AFM Ibrahim","year":"2020","unstructured":"Ibrahim, A. F. M. et al. Antibody RING-mediated destruction of endogenous proteins. Mol. Cell 79, 155\u2013166.e159 (2020).","journal-title":"Mol. Cell"},{"key":"65481_CR40","doi-asserted-by":"publisher","first-page":"7844","DOI":"10.1074\/jbc.M113.544825","volume":"289","author":"AD Portnoff","year":"2014","unstructured":"Portnoff, A. D., Stephens, E. A., Varner, J. D. & DeLisa, M. P. Ubiquibodies, synthetic E3 ubiquitin ligases endowed with unnatural substrate specificity for targeted protein silencing. J. Biol. Chem. 289, 7844\u20137855 (2014).","journal-title":"J. Biol. Chem."},{"key":"65481_CR41","doi-asserted-by":"publisher","first-page":"4945","DOI":"10.18632\/oncotarget.2066","volume":"5","author":"Q Wang","year":"2014","unstructured":"Wang, Q. et al. Engineered ubiquitin ligase PTB-U-box targets insulin\/insulin-like growth factor receptor for degradation and coordinately inhibits cancer malignancy. Oncotarget 5, 4945\u20134958 (2014).","journal-title":"Oncotarget"},{"key":"65481_CR42","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.canlet.2014.12.043","volume":"359","author":"D Zhong","year":"2015","unstructured":"Zhong, D. et al. Chimeric ubiquitin ligases inhibit non-small cell lung cancer via negative modulation of EGFR signaling. Cancer Lett. 359, 57\u201364 (2015).","journal-title":"Cancer Lett."},{"key":"65481_CR43","doi-asserted-by":"publisher","first-page":"7874","DOI":"10.1158\/0008-5472.CAN-05-1581","volume":"65","author":"S Hatakeyama","year":"2005","unstructured":"Hatakeyama, S., Watanabe, M., Fujii, Y. & Nakayama, K. I. Targeted destruction of c-Myc by an engineered ubiquitin ligase suppresses cell transformation and tumor formation. Cancer Res. 65, 7874\u20137879 (2005).","journal-title":"Cancer Res."},{"key":"65481_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-10488-7","volume":"7","author":"AM D\u2019Erchia","year":"2017","unstructured":"D\u2019Erchia, A. M. et al. Massive transcriptome sequencing of human spinal cord tissues provides new insights into motor neuron degeneration in ALS. Sci. Rep. 7, 10046 (2017).","journal-title":"Sci. Rep."},{"key":"65481_CR45","doi-asserted-by":"publisher","first-page":"3410","DOI":"10.1074\/mcp.M113.037291","volume":"13","author":"D Hornburg","year":"2014","unstructured":"Hornburg, D. et al. Deep proteomic evaluation of primary and cell line motoneuron disease models delineates major differences in neuronal characteristics. Mol. Cell Proteom. 13, 3410\u20133420 (2014).","journal-title":"Mol. Cell Proteom."},{"key":"65481_CR46","doi-asserted-by":"publisher","first-page":"4594","DOI":"10.1093\/brain\/awad222","volume":"146","author":"S Bakavayev","year":"2023","unstructured":"Bakavayev, S. et al. Blocking an epitope of misfolded SOD1 ameliorates disease phenotype in a model of amyotrophic lateral sclerosis. Brain 146, 4594\u20134607 (2023).","journal-title":"Brain"},{"key":"65481_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-024-00730-y","volume":"19","author":"Y Jiang","year":"2024","unstructured":"Jiang, Y. et al. Single-domain antibody-based protein degrader for synucleinopathies. Mol. Neurodegener. 19, 44 (2024).","journal-title":"Mol. Neurodegener."},{"key":"65481_CR48","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1080\/15548627.2015.1066957","volume":"11","author":"C Mauvezin","year":"2015","unstructured":"Mauvezin, C. & Neufeld, T. P. Bafilomycin A1 disrupts autophagic flux by inhibiting both V-ATPase-dependent acidification and Ca-P60A\/SERCA-dependent autophagosome-lysosome fusion. Autophagy 11, 1437\u20131438 (2015).","journal-title":"Autophagy"},{"key":"65481_CR49","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/sj.gt.3301905","volume":"10","author":"S K\u00fcgler","year":"2003","unstructured":"K\u00fcgler, S., Kilic, E. & B\u00e4hr, M. Human synapsin 1 gene promoter confers highly neuron-specific long-term transgene expression from an adenoviral vector in the adult rat brain depending on the transduced area. Gene Ther. 10, 337\u2013347 (2003).","journal-title":"Gene Ther."},{"key":"65481_CR50","first-page":"116","volume":"9","author":"KL Jackson","year":"2016","unstructured":"Jackson, K. L., Dayton, R. D., Deverman, B. E. & Klein, R. L. Better targeting, better efficiency for wide-scale neuronal transduction with the synapsin promoter and AAV-PHP.B. Front. Mol. Neurosci. 9, 116 (2016).","journal-title":"Front. Mol. Neurosci."},{"key":"65481_CR51","doi-asserted-by":"publisher","unstructured":"Savell, K. E. et al. A Neuron-Optimized CRISPR\/dCas9 Activation System for Robust and Specific Gene Regulation. eNeuro 6, https:\/\/doi.org\/10.1523\/eneuro.0495-18.2019 (2019).","DOI":"10.1523\/eneuro.0495-18.2019"},{"key":"65481_CR52","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.3390\/ijms23031047","volume":"23","author":"O Bankole","year":"2022","unstructured":"Bankole, O. et al. Beneficial and sexually dimorphic response to combined HDAC inhibitor valproate and AMPK\/SIRT1 pathway activator resveratrol in the treatment of ALS mice. Int. J. Mol. Sci. 23, 1047 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"65481_CR53","doi-asserted-by":"crossref","unstructured":"Martineau, \u00c9., Di Polo, A., Vande Velde, C. & Robitaille, R. Sex-specific differences in motor-unit remodeling in a mouse model of ALS. eNeuro 7, ENEURO.0388-19.2020 (2020).","DOI":"10.1523\/ENEURO.0388-19.2020"},{"key":"65481_CR54","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-015-0271-6","volume":"4","author":"D Cacabelos","year":"2016","unstructured":"Cacabelos, D. et al. Early and gender-specific differences in spinal cord mitochondrial function and oxidative stress markers in a mouse model of ALS. Acta Neuropathol. Commun. 4, 3 (2016).","journal-title":"Acta Neuropathol. Commun."},{"key":"65481_CR55","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-023-00651-2","volume":"19","author":"DJ Rinauro","year":"2024","unstructured":"Rinauro, D. J., Chiti, F., Vendruscolo, M. & Limbocker, R. Misfolded protein oligomers: mechanisms of formation, cytotoxic effects, and pharmacological approaches against protein misfolding diseases. Mol. Neurodegener. 19, 20 (2024).","journal-title":"Mol. Neurodegener."},{"key":"65481_CR56","doi-asserted-by":"publisher","first-page":"eaag0481","DOI":"10.1126\/scitranslmed.aag0481","volume":"9","author":"SL DeVos","year":"2017","unstructured":"DeVos, S. L. et al. Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy. Sci. Transl. Med. 9, eaag0481 (2017).","journal-title":"Sci. Transl. Med."},{"key":"65481_CR57","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1038\/s41591-023-02326-3","volume":"29","author":"CJ Mummery","year":"2023","unstructured":"Mummery, C. J. et al. Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer\u2019s disease: a phase 1b, randomized, placebo-controlled trial. Nat. Med. 29, 1437\u20131447 (2023).","journal-title":"Nat. Med."},{"key":"65481_CR58","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1056\/NEJMoa2204705","volume":"387","author":"TM Miller","year":"2022","unstructured":"Miller, T. M. et al. Trial of antisense oligonucleotide tofersen for SOD1 ALS. N. Engl. J. Med. 387, 1099\u20131110 (2022).","journal-title":"N. Engl. J. Med."},{"key":"65481_CR59","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41591-021-01615-z","volume":"28","author":"VA Korobeynikov","year":"2022","unstructured":"Korobeynikov, V. A., Lyashchenko, A. K., Blanco-Redondo, B., Jafar-Nejad, P. & Shneider, N. A. Antisense oligonuc a therapeutic approach in amyotrophic lateralleotide silencing of FUS expression as sclerosis. Nat. Med. 28, 104\u2013116 (2022).","journal-title":"Nat. Med."},{"key":"65481_CR60","doi-asserted-by":"crossref","unstructured":"Weiss, A. et al. RNAi-mediated silencing of SOD1 profoundly extends survival and functional outcomes in ALS mice. Mol. Ther. 33, 3917\u20133938 (2025).","DOI":"10.1016\/j.ymthe.2025.05.010"},{"key":"65481_CR61","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.omtn.2018.04.015","volume":"12","author":"T Iannitti","year":"2018","unstructured":"Iannitti, T. et al. Translating SOD1 gene silencing toward the clinic: a highly efficacious, off-target-free, and biomarker-supported strategy for fALS. Mol. Ther. Nucleic Acids 12, 75\u201388 (2018).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"65481_CR62","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/S1097-2765(00)00074-5","volume":"6","author":"P Zhou","year":"2000","unstructured":"Zhou, P., Bogacki, R., McReynolds, L. & Howley, P. M. Harnessing the ubiquitination machinery to target the degradation of specific cellular proteins. Mol. Cell 6, 751\u2013756 (2000).","journal-title":"Mol. Cell"},{"key":"65481_CR63","doi-asserted-by":"publisher","first-page":"12729","DOI":"10.1073\/pnas.2133261100","volume":"100","author":"Y Su","year":"2003","unstructured":"Su, Y., Ishikawa, S., Kojima, M. & Liu, B. Eradication of pathogenic beta-catenin by Skp1\/Cullin\/F box ubiquitination machinery. Proc. Natl. Acad. Sci. USA 100, 12729\u201312734 (2003).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"65481_CR64","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3389\/fgene.2018.00029","volume":"9","author":"AJ George","year":"2018","unstructured":"George, A. J., Hoffiz, Y. C., Charles, A. J., Zhu, Y. & Mabb, A. M. A Comprehensive Atlas of E3 Ubiquitin Ligase Mutations in Neurological Disorders. Front. Genet. 9, 29 (2018).","journal-title":"Front. Genet."},{"key":"65481_CR65","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1152\/physiolgenomics.00031.2016","volume":"48","author":"B Medvar","year":"2016","unstructured":"Medvar, B., Raghuram, V., Pisitkun, T., Sarkar, A. & Knepper, M. A. Comprehensive database of human E3 ubiquitin ligases: application to aquaporin-2 regulation. Physiol. Genom. 48, 502\u2013512 (2016).","journal-title":"Physiol. Genom."},{"key":"65481_CR66","doi-asserted-by":"publisher","first-page":"17962","DOI":"10.1074\/jbc.M802283200","volume":"283","author":"JE Tetzlaff","year":"2008","unstructured":"Tetzlaff, J. E. et al. CHIP targets toxic alpha-Synuclein oligomers for degradation. J. Biol. Chem. 283, 17962\u201317968 (2008).","journal-title":"J. Biol. Chem."},{"key":"65481_CR67","doi-asserted-by":"publisher","first-page":"e14695","DOI":"10.1371\/journal.pone.0014695","volume":"6","author":"LV Kalia","year":"2011","unstructured":"Kalia, L. V. et al. Ubiquitinylation of \u03b1-synuclein by carboxyl terminus Hsp70-interacting protein (CHIP) is regulated by Bcl-2-associated athanogene 5 (BAG5). PLoS ONE 6, e14695 (2011).","journal-title":"PLoS ONE"},{"key":"65481_CR68","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1093\/hmg\/ddh083","volume":"13","author":"L Petrucelli","year":"2004","unstructured":"Petrucelli, L. et al. CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. Hum. Mol. Genet. 13, 703\u2013714 (2004).","journal-title":"Hum. Mol. Genet."},{"key":"65481_CR69","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/cr.2010.177","volume":"21","author":"SC Sun","year":"2011","unstructured":"Sun, S. C. Non-canonical NF-\u03baB signaling pathway. Cell Res. 21, 71\u201385 (2011).","journal-title":"Cell Res."},{"key":"65481_CR70","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41419-020-02953-5","volume":"11","author":"S Zhang","year":"2020","unstructured":"Zhang, S., Hu, Z.-w., Mao, C.-y., Shi, C.-h. & Xu, Y. -m. CHIP as a therapeutic target for neurological diseases. Cell Death Dis. 11, 727 (2020).","journal-title":"Cell Death Dis."},{"key":"65481_CR71","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.nbd.2008.10.016","volume":"33","author":"AJ Williams","year":"2009","unstructured":"Williams, A. J., Knutson, T. M., Colomer Gould, V. F. & Paulson, H. L. In vivo suppression of polyglutamine neurotoxicity by C-terminus of Hsp70-interacting protein (CHIP) supports an aggregation model of pathogenesis. Neurobiol. Dis. 33, 342\u2013353 (2009).","journal-title":"Neurobiol. Dis."},{"key":"65481_CR72","doi-asserted-by":"publisher","first-page":"14032","DOI":"10.1038\/mtm.2014.32","volume":"1","author":"F Huda","year":"2014","unstructured":"Huda, F. et al. Distinct transduction profiles in the CNS via three injection routes of AAV9 and the application to generation of a neurodegenerative mouse model. Mol. Ther. Methods Clin. Dev. 1, 14032 (2014).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"65481_CR73","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1093\/hmg\/ddz317","volume":"29","author":"G Massaro","year":"2020","unstructured":"Massaro, G. et al. Systemic AAV9 gene therapy using the synapsin I promoter rescues a mouse model of neuronopathic Gaucher disease but with limited cross-correction potential to astrocytes. Hum. Mol. Genet. 29, 1933\u20131949 (2020).","journal-title":"Hum. Mol. Genet."},{"key":"65481_CR74","doi-asserted-by":"publisher","first-page":"685802","DOI":"10.3389\/fneur.2021.685802","volume":"12","author":"DJ Finneran","year":"2021","unstructured":"Finneran, D. J. et al. Toward development of neuron specific transduction after systemic delivery of viral vectors. Front. Neurol. 12, 685802 (2021).","journal-title":"Front. Neurol."},{"key":"65481_CR75","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1126\/science.8209258","volume":"264","author":"ME Gurney","year":"1994","unstructured":"Gurney, M. E. et al. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science 264, 1772\u20131775 (1994).","journal-title":"Science"},{"key":"65481_CR76","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1097\/WCO.0000000000000730","volume":"32","author":"E Longinetti","year":"2019","unstructured":"Longinetti, E. & Fang, F. Epidemiology of amyotrophic lateral sclerosis: an update of recent literature. Curr. Opin. Neurol. 32, 771\u2013776 (2019).","journal-title":"Curr. Opin. Neurol."},{"key":"65481_CR77","first-page":"1051","volume":"14","author":"P Weydt","year":"2003","unstructured":"Weydt, P., Hong, S. Y., Kliot, M. & M\u00f6ller, T. Assessing disease onset and progression in the SOD1 mouse model of ALS. Neuroreport 14, 1051\u20131054 (2003).","journal-title":"Neuroreport"},{"key":"65481_CR78","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3233\/JND-140068","volume":"2","author":"SR Pfohl","year":"2015","unstructured":"Pfohl, S. R., Halicek, M. T. & Mitchell, C. S. Characterization of the contribution of genetic background and gender to disease progression in the SOD1 G93A mouse model of Amyotrophic Lateral Sclerosis: a meta-analysis. J. Neuromuscul. Dis. 2, 137\u2013150 (2015).","journal-title":"J. Neuromuscul. Dis."},{"key":"65481_CR79","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1080\/17460441.2025.2490248","volume":"20","author":"ML Spitz","year":"2025","unstructured":"Spitz, M. L., Aseel, K. & Benhamou, R. I. Advancing target validation with PROTAC technology. Expert Opin. Drug Discov. 20, 551\u2013563 (2025).","journal-title":"Expert Opin. Drug Discov."},{"key":"65481_CR80","doi-asserted-by":"crossref","unstructured":"Hsia, O. et al. Targeted protein degradation via intramolecular bivalent glues. Nature 627, 204\u2013211 (2024).","DOI":"10.1038\/s41586-024-07089-6"},{"key":"65481_CR81","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ddtec.2019.01.002","volume":"31","author":"M Pettersson","year":"2019","unstructured":"Pettersson, M. & Crews, C. M. PROteolysis TArgeting Chimeras (PROTACs)\u2014past, present and future. Drug Discov. Today Technol. 31, 15\u201327 (2019).","journal-title":"Drug Discov. Today Technol."},{"key":"65481_CR82","first-page":"100413","volume":"4","author":"J Li","year":"2023","unstructured":"Li, J., Chen, X., Lu, A. & Liang, C. Targeted protein degradation in cancers: orthodox PROTACs and beyond. Innovation 4, 100413 (2023).","journal-title":"Innovation"},{"key":"65481_CR83","doi-asserted-by":"publisher","DOI":"10.1186\/s40824-023-00385-8","volume":"27","author":"H Wang","year":"2023","unstructured":"Wang, H. et al. Beyond canonical PROTAC: biological targeted protein degradation (bioTPD). Biomater. Res. 27, 72 (2023).","journal-title":"Biomater. Res."},{"key":"65481_CR84","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/17460441.2019.1667329","volume":"15","author":"R Cacabelos","year":"2020","unstructured":"Cacabelos, R. How plausible is an Alzheimer\u2019s disease vaccine?. Expert Opin. Drug Discov. 15, 1\u20136 (2020).","journal-title":"Expert Opin. Drug Discov."},{"key":"65481_CR85","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1038\/s41586-023-06415-8","volume":"620","author":"JL Watson","year":"2023","unstructured":"Watson, J. L. et al. De novo design of protein structure and function with RFdiffusion. Nature 620, 1089\u20131100 (2023).","journal-title":"Nature"},{"key":"65481_CR86","doi-asserted-by":"publisher","unstructured":"Bennett, N. R. et al. Atomically accurate de novo design of single-domain antibodies. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2024.03.14.585103 (2024).","DOI":"10.1101\/2024.03.14.585103"},{"key":"65481_CR87","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1523\/JNEUROSCI.4253-04.2005","volume":"25","author":"BJ Turner","year":"2005","unstructured":"Turner, B. J. et al. Impaired extracellular secretion of mutant superoxide dismutase 1 associates with neurotoxicity in familial amyotrophic lateral sclerosis. J. Neurosci. 25, 108\u2013117 (2005).","journal-title":"J. Neurosci."},{"key":"65481_CR88","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1021\/acschemneuro.8b00527","volume":"10","author":"NE Farrawell","year":"2019","unstructured":"Farrawell, N. E., Yerbury, M. R., Plotkin, S. S., McAlary, L. & Yerbury, J. J. CuATSM protects against the in vitro cytotoxicity of wild-type-like copper-zinc superoxide dismutase mutants but not mutants that disrupt metal Binding. ACS Chem. Neurosci. 10, 1555\u20131564 (2019).","journal-title":"ACS Chem. Neurosci."},{"key":"65481_CR89","first-page":"69a","volume":"43","author":"R Klebe","year":"1969","unstructured":"Klebe, R. Neuroblastoma: cell culture analysis of a differentiating stem cell system. J. Cell Biol. 43, 69a (1969).","journal-title":"J. Cell Biol."},{"key":"65481_CR90","first-page":"741","volume":"71","author":"RA Ross","year":"1983","unstructured":"Ross, R. A., Spengler, B. A. & Biedler, J. L. Coordinate morphological and biochemical interconversion of human neuroblastoma cells. J. Natl. Cancer Inst. 71, 741\u2013747 (1983).","journal-title":"J. Natl. Cancer Inst."},{"key":"65481_CR91","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1099\/0022-1317-36-1-59","volume":"36","author":"FL Graham","year":"1977","unstructured":"Graham, F. L., Smiley, J., Russell, W. C. & Nairn, R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36, 59\u201374 (1977).","journal-title":"J. Gen. Virol."},{"key":"65481_CR92","doi-asserted-by":"publisher","first-page":"101612","DOI":"10.1016\/j.jbc.2022.101612","volume":"298","author":"L McAlary","year":"2022","unstructured":"McAlary, L., Shephard, V. K., Wright, G. S. A. & Yerbury, J. J. A copper chaperone-mimetic polytherapy for SOD1-associated amyotrophic lateral sclerosis. J. Biol. Chem. 298, 101612 (2022).","journal-title":"J. Biol. Chem."},{"key":"65481_CR93","doi-asserted-by":"publisher","first-page":"499","DOI":"10.3389\/fnins.2016.00499","volume":"10","author":"L McAlary","year":"2016","unstructured":"McAlary, L., Aquilina, J. A. & Yerbury, J. J. Susceptibility of mutant SOD1 to form a destabilized monomer predicts cellular aggregation and toxicity but not in vitro aggregation propensity. Front. Neurosci. 10, 499 (2016).","journal-title":"Front. Neurosci."},{"key":"65481_CR94","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-32835-y","volume":"8","author":"E Pokrishevsky","year":"2018","unstructured":"Pokrishevsky, E. et al. Tryptophan 32-mediated SOD1 aggregation is attenuated by pyrimidine-like compounds in living cells. Sci. Rep. 8, 15590 (2018).","journal-title":"Sci. Rep."},{"key":"65481_CR95","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1083\/jcb.114.3.503","volume":"114","author":"MH Symons","year":"1991","unstructured":"Symons, M. H. & Mitchison, T. J. Control of actin polymerization in live and permeabilized fibroblasts. J. Cell Biol. 114, 503\u2013513 (1991).","journal-title":"J. Cell Biol."},{"key":"65481_CR96","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/0003-2697(71)90370-8","volume":"44","author":"C Beauchamp","year":"1971","unstructured":"Beauchamp, C. & Fridovich, I. Superoxide dismutase: improved assays and an assay applicable to acrylamide gels. Anal. Biochem. 44, 276\u2013287 (1971).","journal-title":"Anal. Biochem."},{"key":"65481_CR97","doi-asserted-by":"publisher","first-page":"3780","DOI":"10.1016\/j.celrep.2019.05.103","volume":"27","author":"S Chen","year":"2019","unstructured":"Chen, S. et al. CRISPR-READI: efficient generation of knockin mice by CRISPR RNP electroporation and AAV donor infection. Cell Rep. 27, 3780\u20133789.e3784 (2019).","journal-title":"Cell Rep."},{"key":"65481_CR98","first-page":"53257","volume":"6","author":"T Hatzipetros","year":"2015","unstructured":"Hatzipetros, T. et al. A quick phenotypic neurological scoring system for evaluating disease progression in the SOD1-G93A mouse model of ALS. J. Vis. Exp. 6, 53257 (2015).","journal-title":"J. Vis. Exp."},{"key":"65481_CR99","first-page":"1021","volume":"33","author":"M Ferrucci","year":"2018","unstructured":"Ferrucci, M. et al. In search for a gold-standard procedure to count motor neurons in the spinal cord. Histol. Histopathol. 33, 1021\u20131046 (2018).","journal-title":"Histol. Histopathol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-65481-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-65481-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-65481-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T10:02:21Z","timestamp":1762768941000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-65481-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,10]]},"references-count":99,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["65481"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-65481-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6070925\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,10]]},"assertion":[{"value":"20 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"N.R.C., C.C.G. and J.J.Y. are named inventors on a provisional patent application (PCT\/CA2024\/050200) filed by the University of British Columbia and the University of Wollongong and assigned to ProMIS Neurosciences, pertaining to sequences of antibody and ubiquitin ligase fusion proteins for misfolded superoxide dismutase 1. N.R.C. is the Chief Scientific Officer of ProMIS Neurosciences. N.R.C. has received consultation compensation from ProMIS and possesses ProMIS stock and stock options. L.M.I. is the Chief Scientific & Medical Officer, founder and shareholder of Celosia Therapeutics. All other authors declare that they have no competing interests with the contents of this article.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9713"}}